7TM and Dr Reddy’s join hands in drug discovery

Under the terms of the agreement, 7TM Pharma and Dr Reddy’s will collaborate to identify clinical candidates for pre-selected targets. Both the parties will jointly develop these candidates from the preclinical stage up to Phase IIa (proof-of-concept). On successful completion of a Phase IIa study, the companies may either license-out the candidate for further development and commercialization to a larger pharmaceutical company or continue the further co-development and commercialization jointly.

Mette Kirstine Agger, CEO of 7TM Pharma, said: “It is exciting to be working with Dr Reddy’s, as they have developed strong R&D capabilities and combining this with 7TMs expertise in the GPCR area and SD3 (7TM’s technology platform) we are looking forward to a fruitful collaboration.”